Loading clinical trials...
Loading clinical trials...
An Interventional Open-label, Single-group, Phase I/II Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Adult Patients With Relapsed or Refractory Forms of B-cell Lymphoproliferative Disorders
Conditions
Interventions
Hem101
Locations
1
Russia
National Medical Research Center for Hematology
Moscow, Russia
Start Date
November 26, 2024
Primary Completion Date
October 17, 2025
Completion Date
November 17, 2025
Last Updated
February 9, 2026
NCT07326930
NCT06008691
NCT06534437
NCT05312801
NCT03740334
NCT06318884
Lead Sponsor
National Research Center for Hematology, Russia
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions